SeaCrest Wealth Management LLC Purchases 75 Shares of Zoetis Inc. (NYSE:ZTS)

SeaCrest Wealth Management LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 2.0% in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,860 shares of the company’s stock after buying an additional 75 shares during the period. SeaCrest Wealth Management LLC’s holdings in Zoetis were worth $669,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of ZTS. Private Wealth Management Group LLC acquired a new position in shares of Zoetis during the fourth quarter valued at about $33,000. Webster Bank N. A. grew its holdings in shares of Zoetis by 89.1% during the first quarter. Webster Bank N. A. now owns 174 shares of the company’s stock valued at $29,000 after buying an additional 82 shares during the last quarter. Gladius Capital Management LP acquired a new position in shares of Zoetis during the fourth quarter valued at about $40,000. Neo Ivy Capital Management bought a new position in shares of Zoetis during the fourth quarter valued at about $40,000. Finally, EdgeRock Capital LLC bought a new position in shares of Zoetis during the fourth quarter valued at about $45,000. 92.80% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have commented on ZTS shares. Piper Sandler lifted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 14th. BTIG Research lifted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th. The Goldman Sachs Group lowered their price target on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. Finally, Barclays lowered their price target on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Buy” and a consensus price target of $217.11.

Zoetis Price Performance

NYSE:ZTS traded down $0.95 during mid-day trading on Tuesday, hitting $183.53. 536,795 shares of the stock traded hands, compared to its average volume of 2,738,513. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. Zoetis Inc. has a 12-month low of $144.80 and a 12-month high of $201.92. The company has a market cap of $83.15 billion, a PE ratio of 35.55, a price-to-earnings-growth ratio of 2.81 and a beta of 0.86. The business’s 50-day moving average price is $177.89 and its 200 day moving average price is $175.08.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. The company had revenue of $2.36 billion during the quarter, compared to analyst estimates of $2.31 billion. Zoetis had a return on equity of 50.67% and a net margin of 26.29%. The firm’s revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter last year, the company earned $1.41 EPS. On average, analysts expect that Zoetis Inc. will post 5.84 EPS for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be paid a $0.432 dividend. The ex-dividend date is Thursday, July 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 0.94%. Zoetis’s dividend payout ratio (DPR) is currently 33.33%.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.